Armata Pharmaceuticals

Armata Pharmaceuticals

  • Founded: 1989
  • Location: Marina del Rey, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1b/Clin2
  • Therapy area: P. aeruginosa infections in cystic fibrosis
  • Drug types: INF
  • Lead product: AP-PA02
  • Product link:
  • Funding: $45M stock Mar 2022

job board

Short description:

Natural and synthetic bacteriophage-based therapies

Drug notes:

Also Clin0 NCFB infection; AP-SA02 Clin1b/Clin2a S. aureus bacteremia, Clin0 PJI; AP-PA03 Clin0 pneumonia; 2 undisclosed programs RD infections

Long description:

Armata Pharmaceuticals is creating bacteriophage therapeutics to meet the global challenge of antibiotic resistance. Antibiotic resistance is increasing making it harder to treat common infections creating a major threat to public health. As an alternative, Armata is harnessing the power of natural and synthetic phages that infect and rapidly kill bacteria. The advantage of this approach over traditional antibacterial therapies is that the typical life cycle of a lytic phage only stops once the pathogenic bacteria have been eliminated. Moreover, phage activity is independent of antibiotic resistance and they are highly specific to a bacterial host, circumventing microbiome damage. Armata’s lead phage programs are against Pseudomonas aeruginosa for cystic fibrosis and Staphylococcus aureus.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy